Globus Medical Valuation Multiples

Globus Medical is valued at $9.3B as of November 2026, a 2.9x revenue multiple. In the last 12 months, Globus Medical revenue was $3.1B and Globus Medical EBITDA was $1.1B.

Globus Medical Overview

About Globus Medical

Through innovative technology and M&A activity, Globus Medical transformed into the number two medical device manufacturer in the competitive spine market. The firm was founded in 2003 with a heavy focus on internal research and development but vaulted its market share in 2023 through a merger with former competitor NuVasive. In 2025, the company acquired Nevro, a smaller player that specialized in spinal cord stimulation therapy. Globus Medical reports two business segments, musculoskeletal solutions and enabling technologies, which consist of implants used in surgery and associated technologies that assist the physician.


Founded

2003

HQ

United States

Employees

6.0K

Financials (LTM)

Revenue: $3.1B
EBITDA: $1.1B

EV

$8.9B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Globus Medical Financials

Globus Medical reported last 12-month revenue of $3.1B and EBITDA of $1.1B.

In the same LTM period, Globus Medical generated $2.1B in gross profit, $1.1B in EBITDA, and $665M in net income.

Revenue (LTM)


Globus Medical P&L

In the most recent fiscal year, Globus Medical reported revenue of $2.9B and EBITDA of $875M.

Globus Medical is profitable as of last fiscal year, with gross margin of 67%, EBITDA margin of 30%, and net margin of 18%.

See analyst estimates for Globus Medical
LTMLast FY202320242025202620272028
Revenue$3.1B$2.9B$1.6B$2.5B$2.9B
Gross Profit$2.1B$2B$1B$1.5B$2B
Gross Margin69%67%65%59%67%
EBITDA$1.1B$875M$347M$474M$875M
EBITDA Margin34%30%22%19%30%
EBIT Margin27%18%13%9%18%
Net Profit$665M$538M$123M$103M$538M
Net Margin22%18%8%4%18%
Net Debt-($408M)---

Financial data powered by Morningstar, Inc.

Globus Medical Stock Performance

Globus Medical has current market cap of $9.3B, and enterprise value of $8.9B.

Market Cap Evolution


Globus Medical's stock price is $69.99.

Globus Medical share price decreased by 10.3% in the last 30 days, and by 23.1% in the last year.

Globus Medical has an EPS (earnings per share) of $4.06.

See more trading valuation data for Globus Medical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$8.9B$9.3B-0.7%-10.3%-14.0%-23.1%$4.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Globus Medical Valuation Multiples

Globus Medical trades at 2.9x EV/Revenue multiple, and 8.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Globus Medical

EV / Revenue (LTM)


Globus Medical Financial Valuation Multiples

As of November 18, 2026, Globus Medical has market cap of $9.3B and EV of $8.9B.

Globus Medical has a P/E ratio of 13.9x.

LTMLast FY202320242025202620272028
EV/Revenue2.9x3.0x5.7x3.5x3.0x
EV/EBITDA8.4x10.1x25.6x18.7x10.1x
EV/EBIT10.6x16.5x43.9x40.3x16.5x
EV/Gross Profit4.1x4.5x8.7x6.0x4.5x
P/E13.9x17.2x75.5x90.0x17.2x
EV/FCF13.5x15.3x53.6x21.9x15.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Globus Medical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Globus Medical Margins & Growth Rates

Globus Medical grew revenue by 5% and EBITDA by 22% in the last fiscal year.

In the most recent fiscal year, Globus Medical reported gross margin of 67%, EBITDA margin of 30%, and net margin of 18%.

See estimated margins and future growth rates for Globus Medical

Globus Medical Margins

Last FY202420252026202720282029
Gross Margin67%59%67%70%
EBITDA Margin30%19%30%34%
EBIT Margin18%9%18%28%
Net Margin18%4%18%22%
FCF Margin20%16%20%23%

Globus Medical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%61%17%5%
Gross Profit Growth9%45%34%9%
EBITDA Growth22%37%85%22%
EBIT Growth60%9%145%60%
Net Profit Growth27%(16%)422%27%
FCF Growth24%145%43%24%

Data powered by FactSet, Inc. and Morningstar, Inc.

Globus Medical Operational KPIs

Globus Medical's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.

Globus Medical's Rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Globus Medical's Rule of X is 48% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Globus Medical
LTMLast FY202320242025202620272028
Rule of 4040%40%---
Bessemer Rule of X48%48%---
Revenue per Employee-$0.5M---
Opex per Employee-$0.2M---
R&D Expenses to Revenue5%5%8%6%5%
Opex to Revenue-49%52%50%49%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Globus Medical Competitors

Globus Medical competitors include Bruker, Bio-Rad Laboratories, Insulet, Sysmex, Shimadzu, Demant, Bausch + Lomb, Getinge, Snibe and Fresenius Medical Care.

Most Globus Medical public comparables operate across Medical Devices, DeepTech and HealthTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Bruker$3.4B$288M3.2x3.1x38.1x17.3x
Bio-Rad Laboratories$2.6B$1.1B3.7x3.7x8.5x21.6x
Insulet$2.7B$455M3.9x3.2x23.0x13.0x
Sysmex$3.1B$621M2.6x2.4x13.1x12.1x
Shimadzu$3.5B$630M2.2x2.1x12.5x12.2x
Demant$3.4B$748M4.0x3.5x18.1x14.3x
Bausch + Lomb$5.1B$513M2.4x2.3x23.7x11.4x
Getinge$3.5B$576M2.4x2.3x14.4x11.5x

This data is available for Pro users. Sign up to see all Globus Medical competitors and their valuation data.

Start Free Trial

Acquisitions by Globus Medical

Globus Medical has acquired 12 companies to date.

Last acquisition by Globus Medical was on November 3rd 2026. Globus Medical acquired Synaptive Medical for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Globus Medical

Synaptive Medical
Higgs Boson
Nevro
NuVasive
Description
Toronto-headquartered Synaptive Medical is a neurosurgery technology company developing the BrightMatter system for integrated imaging, navigation, and robotic microscopy. Its modular platforms automate microscope control and provide real-time 3D visualization during brain and spine procedures. Founded in 2012 in Ontario, Canada, the firm advances patient outcomes by streamlining operating room workflows across neurological interventions.
Higgs Boson Health is a Boston-based digital health platform providing patient engagement tools for surgical and interventional procedures. The service offers preoperative education, remote monitoring, and recovery tracking via mobile apps integrated with electronic health records at hospitals like Massachusetts General. Launched in 2020, it reduces readmissions through AI-driven personalized care plans.
Nevro is a global medical device company headquartered in Redwood City, California, that specializes in neuromodulation for chronic pain management. The firm commercializes the Senza spinal cord stimulation system, distinguished by its HF10 therapy delivering high-frequency waveforms at 10 kHz. FDA-approved for back, leg, and intractable pain, Senza treats conditions without paresthesia. Nevro serves patients through physicians in the United States, Europe, and Australia.
NuVasive is a San Diego-based medical technology company developing products for minimally invasive spine surgery. Its portfolio includes the Pulse platform integrating imaging, neuromonitoring, and implants like CoRoent XL cages and Modulus cervical plates. NuVasive serves spine surgeons globally with solutions for lumbar, cervical, and thoracolumbar procedures. Founded in 1999, the company operates in over 20 countries with manufacturing in the U.S. and Europe.
HQ CountryCanadaUnited StatesUnited StatesUnited States
HQ City
Toronto
Durham, NC
San Francisco, CA
San Diego, CA
Deal Date3 Nov 202626 Aug 20266 Feb 20259 Feb 2023
Valuationundisclosedundisclosed$250M$3.1B
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Globus Medical acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Globus Medical

When was Globus Medical founded?Globus Medical was founded in 2003.
Where is Globus Medical headquartered?Globus Medical is headquartered in United States.
How many employees does Globus Medical have?As of today, Globus Medical has over 6K employees.
Who is the CEO of Globus Medical?Globus Medical's CEO is Keith W. Pfeil.
Is Globus Medical publicly listed?Yes, Globus Medical is a public company listed on NYSE.
What is the stock symbol of Globus Medical?Globus Medical trades under GMED ticker.
When did Globus Medical go public?Globus Medical went public in 2012.
Who are competitors of Globus Medical?Globus Medical main competitors include Bruker, Bio-Rad Laboratories, Insulet, Sysmex, Shimadzu, Demant, Bausch + Lomb, Getinge, Snibe, Fresenius Medical Care.
What is the current market cap of Globus Medical?Globus Medical's current market cap is $9.3B.
What is the current revenue of Globus Medical?Globus Medical's last 12 months revenue is $3.1B.
What is the current revenue growth of Globus Medical?Globus Medical revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of Globus Medical?Current revenue multiple of Globus Medical is 2.9x.
What is the current EBITDA of Globus Medical?Globus Medical's last 12 months EBITDA is $1.1B.
What is Globus Medical's EBITDA margin?Globus Medical's last 12 months EBITDA margin is 34%.
What is the current EV/EBITDA multiple of Globus Medical?Current EBITDA multiple of Globus Medical is 8.4x.
What is the current FCF of Globus Medical?Globus Medical's last 12 months FCF is $657M.
What is Globus Medical's FCF margin?Globus Medical's last 12 months FCF margin is 21%.
What is the current EV/FCF multiple of Globus Medical?Current FCF multiple of Globus Medical is 13.5x.
How many companies Globus Medical has acquired to date?As of November 2026, Globus Medical has acquired 12 companies.
What was the largest acquisition by Globus Medical?$3.1B acquisition of NuVasive on 9th February 2023 was the largest M&A Globus Medical has done to date.
What companies Globus Medical acquired?Globus Medical acquired NuVasive, Nevro, Alphatec Spine (international distribution unit), Branch Medical Group, Transplant Technologies of Texas, KB Medical, StelKast, Synoste Oy, Surgimap, Synaptive Medical, and 2 other companies.
In how many companies Globus Medical has invested to date?Globus Medical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Globus Medical

Lists including Globus Medical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial